RESUMO
The formulation of drug with improved bioavailability is always challenging and indispensable in the field of pharmaceutics. The control of intermolecular interactions via crystal engineering approach and solid-state molecular recognition results in the formation of active drug molecules with modulated pharmacological benefits. Therefore, with the aim to improve the solubility and dissolution rate of the drug chlorpropamide (CPA), the mechanochemical liquid-assisted grinding (LAG) of the drug with several pharmaceutically accepted excipients was performed. This contributed to the discovery of six novel solid phases, namely salts, salt cocrystals and salt cocrystal hydrateâthe salt of CPA with 3, 4-diaminopyridine (DAP); salt and salt cocrystal (SC) polymorph (Zâ³=3) with 1, 4-diazabicyclo [2.2.2] octane (DABCO); a salt, SC polymorph (Zâ³=9), and a SC hydrate (Zâ³=9) with piperazine (PIP). The formation of these salts and salt cocrystals are mainly guided by the strong hydrogen bonds with tunable strength having high electrostatic contribution. This attractive interaction brings the donor and the acceptor atoms close to each other for a facile proton transfer. Furthermore, the conformational constraints on the drug molecules, provided by the excipients via strong and directional hydrogen bonds, are quite impressive as this leads to the identification and characterization of "new conformational isomers" for the CPA molecules. The new crystalline phases exhibit enhanced intrinsic dissolution rate in comparison to that of the pure drug, the magnitude being 7, 131, and 120 folds for CPADAP, CPADABCO_II, and CPAPIP_III, respectively. Furthermore, it is interesting to note that the order of solubility is enhanced by 2.7-, 3-, and 7-fold, respectively, for the abovementioned salts. This also mirrors the trends in the magnitude of the binding energy, the higher magnitude being reflected in the lower solubility. Additionally, the in vivo experiments performed in SD rats results in the enhancement of the magnitude of the pharmacokinetic properties, when compared to the pristine drug. The concentration of the drug in CPADABCO_II and CPAPIP_III formulations exhibits 6- and 4-fold increments, respectively. Indeed, these results corroborate to the trends observed in the structural characterization, intermolecular energy calculations, solubility, and in vitro dissolution assessments.
Assuntos
Clorpropamida , Cristalização , Ligação de Hidrogênio , Sais , Solubilidade , Cristalização/métodos , Sais/química , Clorpropamida/química , Química Farmacêutica/métodos , Excipientes/química , Composição de Medicamentos/métodos , Animais , Ratos , Disponibilidade BiológicaRESUMO
An electrochemical method was developed to accomplish the reagentless synthesis of 4,5-disubstituted triazole derivatives employing secondary propargyl alcohol as C-3 synthon and sodium azide as cycloaddition counterpart. The reaction was conducted at room temperature in an undivided cell with a constant current using a pencil graphite (C) anode and stainless-steel cathode in a MeCN solvent system. The proposed reaction mechanism was convincingly established by carrying out a series of control experiments and further supported by electrochemical and density functional theory (DFT) studies.
RESUMO
Herein, we present the first examples of air-stable, deep-lowest unoccupied molecular orbital (LUMO) polycyclic aromatic molecules with emission in the near-infrared (NIR) region, using nitration as a strategy. Despite the fact that nitroaromatics are non-emissive, the choice of a comparatively electron-rich terrylene core proved to be beneficial for achieving fluorescence in these molecules. The extent of nitration proportionately stabilized the LUMOs. Tetra-nitrated terrylene diimide exhibited a deep-LUMO (≤-4.5 eV) of -5.0 eV vs. Fc/Fc+, the lowest for any larger RDIs. These are also the only examples of emissive nitro-RDIs, with larger quantum yields.